The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels

被引：0
|
作者：
Flint, A. [1 ]
Kapitza, C. [2 ]
Hindsberger, C. [1 ]
Zdravkovic, M. [1 ]
机构：
[1] Novo Nordisk AS, Global Dev, DK-2880 Bagsvaerd, Denmark
[2] Profil Inst Stoffivechselforsch GmbH, Neuss, Germany
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
887
引用
收藏
页码：S354 / S354
页数：1
相关论文
共 50 条
  • [21] The long-acting human GLP-1 analogue liraglutide given once daily significantly improves glycaemic control by reducing fasting and postprandial glucose levels in subjects of Japanese origin with type 2 diabetes
    Seino, Y.
    Kaku, K.
    Nishijima, K.
    Rasmussen, M. F.
    Zdravkovic, M.
    Kristensen, P.
    DIABETOLOGIA, 2007, 50 : S352 - S352
  • [22] Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
    Seino, Y.
    Rasmussen, M. F.
    Nishida, T.
    Kaku, K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1013 - 1022
  • [23] The once-daily human GLP-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice through both acute and chronic action mechanisms
    Shimoda, M.
    Kanda, Y.
    Tawaramoto, K.
    Hashiramoto, M.
    Matsuki, M.
    Kaku, K.
    DIABETOLOGIA, 2008, 51 : S210 - S210
  • [24] Treatment satisfaction in patients with type 2 diabetes is significantly improved with liraglutide, the once-daily GLP-1 analogue versus sitagliptin, both combined with metformin
    Montanya Mias, E.
    Cuddihy, R.
    Pratley, R.
    Hammer, M.
    Thomsen, A.
    Davies, M. J.
    DIABETOLOGIA, 2010, 53
  • [25] A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure
    Fonseca, V.
    Falahati, A.
    Zychma, M.
    Madsbad, S.
    Plutzky, J.
    DIABETOLOGIA, 2009, 52 : S299 - S299
  • [26] Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride
    Bode, B. W.
    Hale, P. M.
    Hammer, M.
    Testa, M. A.
    Garber, A.
    DIABETOLOGIA, 2008, 51 : S357 - S358
  • [27] The once-daily human GLP-1 analogue liraglutide increases the beta cell mass in normoglycaemic mice by directly accelerating cell differentiation and proliferation
    Shimoda, M.
    DIABETOLOGIA, 2009, 52 : S34 - S35
  • [28] The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects
    Jiang, Ji
    Zhang, Jianyan
    Jacobsen, Lisbeth V.
    Hu, Pei
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1620 - 1627
  • [29] Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
    Horowitz, Michael
    Flint, Anne
    Jones, Karen L.
    Hindsberger, Charlotte
    Rasmussen, Mads F.
    Kapitza, Christoph
    Doran, Selena
    Jax, Thomas
    Zdravkovic, Milan
    Chapman, Ian M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (02) : 258 - 266
  • [30] Pharmacokinetic modelling of the once-daily human GLP-1 analogue liragiutide in healthy volunteers and comparison to exenatide
    Jonker, Daniel
    Toft, Anders D.
    Kristensen, Peter
    Knudsen, Lotte
    Watson, Estelle
    DIABETES, 2007, 56 : A160 - A160
12345